

Improved Quality of Life in Patients with Gastroenteropancreatic NETs with Lutetium PRRT

Saravana-Bawan B¹, Wieler M², Koumna S³, McMullen T¹, McEwan A³

¹Department of Surgery, University of Alberta, ²Department of Physical Therapy, University of Alberta, ³Department of Oncology, University of Alberta

TAP TO GO BACK
TO KIOSK MENU

Background

- The incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is increasing
- Lutetium therapy is an established treatment with benefit towards progression-free survival (PFS) in metastatic GEP-NETs with median PFS of up to 36 months
- The effect of ¹⁷⁷Lu-DOTATATE on quality of life (QoL) is not yet well established
- Symptoms are diverse and related to both tumor burden and function
- The impact of treatment on patient QoL must be considered with the goal of improvement or maintenance in patient function and symptom control.

Methods (Click)

Study Design

- Prospective non-randomized open label phase II clinical trial
- Enrollment April 29, 2014 - ongoing

Study Population

- Age ≥ 14 to 90 y.o.
- Metastatic un-resectable GEP-NETs
- Somatostatin receptor positive with size at least 1.5cm
- Bloodwork within accepted range

QoL Assessment

- EORTC QLQ-C30 and GI.NET21
- At baseline and prior to every treatment

Data Analysis

- STATA 15
- Repeated measures ANOVA

Results (Click)

- 85 patients included for analysis
 - 68% G.I. 24% pancreatic and 11% unknown but suspected GI primary
- Relatively high baseline mean global health status of 68.1
- Mean global health status maintained after four treatment cycles
- Clinically and statistically significant improvement in insomnia, endocrine symptoms and G.I. symptoms
- Clinically significant improvement in mean social functioning,,
- No statistically or clinically significant deterioration in any QoL parameters assessed

Discussion

- Unique to our study we establish improved aspects of QoL in patients with GEP-NETs with documented progression at baseline
- Our population is very representative of that found in clinical practice and can be applied directly
- Critically, endocrine and G.I. symptoms were improved which remain some of the most difficult to treat symptoms in patients with NETs
- Further analysis at study completion will assess if these benefits are maintained over a prolonged treatment course in our modified protocol

Conclusion


¹⁷⁷Lu-DOTATATE is not only effective in improving PFS for patients with metastatic GEP-NETs but also maintains overall quality of life and importantly provides patients with improvement in specific symptoms such as insomnia, endocrine and GI symptoms

Correspondence

Bianka Saravana-Bawan, MD
Bianka@ualberta.ca

Figure 1. QLQ C-30 Scores

EORTC QLQ-C30



Disclosure



The authors have no financial relationships to disclose

Acknowledgements



Materials and Methods

TAP TO GO BACK TO KIOSK MENU



Exclusion:

- Patients with a history of severe renal impairment (creatinine clearance < 30 mL/min)
- Patients with a history of severe liver impairment (total bilirubin > 3x ULN)
- Patients with a history of severe hematologic impairment (hemoglobin < 10 g/dL, platelets < 100,000/mm³, or neutrophils < 1,500/mm³)
- Patients with a history of severe cardiac impairment (left ventricular ejection fraction < 50%)
- Patients with a history of severe pulmonary impairment (FEV1 < 50% predicted)
- Patients with a history of severe gastrointestinal impairment (dysphagia, severe constipation, or severe diarrhea)
- Patients with a history of severe neurological impairment (seizures, severe headache, or severe dizziness)
- Patients with a history of severe endocrine impairment (hypothyroidism, hyperthyroidism, or severe diabetes)
- Patients with a history of severe immunologic impairment (autoimmune disease, severe allergic reactions, or severe drug allergies)
- Patients with a history of severe infectious disease (active infection, severe bacterial infection, or severe viral infection)
- Patients with a history of severe organ transplant (kidney, liver, or lung transplant)
- Patients with a history of severe organ failure (kidney failure, liver failure, or lung failure)
- Patients with a history of severe organ dysfunction (kidney dysfunction, liver dysfunction, or lung dysfunction)
- Patients with a history of severe organ impairment (kidney impairment, liver impairment, or lung impairment)
- Patients with a history of severe organ damage (kidney damage, liver damage, or lung damage)
- Patients with a history of severe organ injury (kidney injury, liver injury, or lung injury)
- Patients with a history of severe organ trauma (kidney trauma, liver trauma, or lung trauma)
- Patients with a history of severe organ surgery (kidney surgery, liver surgery, or lung surgery)
- Patients with a history of severe organ resection (kidney resection, liver resection, or lung resection)
- Patients with a history of severe organ transplantation (kidney transplantation, liver transplantation, or lung transplantation)
- Patients with a history of severe organ donation (kidney donation, liver donation, or lung donation)
- Patients with a history of severe organ donation (kidney donation, liver donation, or lung donation)
- Patients with a history of severe organ donation (kidney donation, liver donation, or lung donation)

Lutetium Treatment

- Typical regimens consist of a maximum of four cycles of Lu with mean activity 5.2-5.55GBq per cycle
- Our protocol: up to 12 cycles
 - Induction: 4 cycles of up to 5.55GBq per cycle q10weeks
 - Maintenance: up to 8 cycles of low dose 3.7GBq per cycle q6months

QoL Assessment

- Questionnaire administered at baseline and each follow-up visit
- European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire, Version 3.0 (QLQ-C30)
 - - Validated patient based QoL questionnaire
 - - 30 questions assessing parameters through single or multi item questions
 - - Global Health Status, functional scales, symptom scales
 - - All parameter scores transformed to 100 point scale
- EORTC QLQ-GI.NET 21
 - - Validated QoL questionnaire specifically for G.I. related neuroendocrine tumors
 - - Adjunct to EORTC QLQ-C30
- Clinically significant changes are established as mean score change of at least **5 to 10** points

Therapy Number	Year	Frequency	Evaluations
Induction 1 - 4	1	Every 10 - 12 weeks	CT/MRI scans and blood work/urine 4 months after therapy 4.
Maintenance 5 - 6	2	Every 6 months (range 5 – 8 months)	CT/MRI scans and blood work/urine 4 months after therapy 5 & 6.
7 - 8	3	Every 6 months (range 5 – 9 months)	CT/MRI scans and blood work/urine 4 months after therapy 7 & 8.
9 +	4	Every 6 - 9 months (range 6 – 12 months)	CT/MRI scans and blood work/urine 4 months after each subsequent therapy.

TAP TO GO BACK TO KIOSK MENU

Results

Table 1. Patient Characteristics		
	N	(%)
	(n=85)	
Age		
20-49	10	11
50-69	49	57
70-90	26	31
Sex		
Male	49	58
Female	36	42
ECOG		
0	54	64
1	27	32
2	4	5
Previous Treatment		
Surgery	62	73
SSA	61	72
Chemotherapy	12	14
mTOR, TKI	5	6
Locoregional Therapy	6	7

Table 3. EORTC QLQ C-30 and GI.NET21

EORTC scale	Mean (p-value)	
	Baseline	Post Treatment 4
Global Health Status	68.1 [60.57, 75.62]	66.4 [57.33, 75.52]
Functional Scales		
Physical Functioning	80.50 [73.76, 87.25]	82.13 [75.86, 88.41]
Role Functioning	76.74 [68.14, 85.35]	77.13 [67.9, 86.36]
Emotional Functioning	70.14 [62.15, 78.13]	73.15 [64.51, 81.78]
Cognitive Functioning	75.0 [65.52, 84.48]	76.39 [66.45, 86.33]
Social Functioning	76.85 [68.09, 85.62]	83.33** [75.02, 91.64]
Symptom Scales		
Fatigue	32.56 [24.78, 40.36]	30.36 [22.57, 38.15]
Nausea and Vomiting	5.04 [1.77, 8.31]	6.98 [1.47, 12.49]
Pain	24.81 [16.40, 33.21]	22.48 [13.68, 31.29]
Dyspnea	19.38 [10.36, 28.40]	21.71 [13.99, 29.42]
Insomnia	36.43 [26.47, 46.40]	25.58** [16.96, 34.20]
Appetite Loss	12.40 [6.06, 18.74]	11.63 [5.76, 17.50]
Constipation	13.18 [6.05, 20.31]	11.63 [2.30, 20.26]
Diarrhea	36.19 [26.42, 45.96]	31.43 [21.83, 41.03]
Financial Difficulties	20.0 [10.71, 29.29]	20.95 [11.71, 30.20]
Endocrine Symptoms	20.37 [13.58, 27.16]	14.81** [9.37, 20.26]
GI Symptoms	22.28 [16.16, 28.39]	16.67** [12.17, 21.17]

** P < 0.05

Table 2. NET Diagnosis		
	N (n=85)	(%)
Site of Primary		
Pancreas	20	24
GI	58	68
Unknown Primary (presumptive GNET)	9	11
Metastasis		
Liver	77	91
Bone	19	22
Mesentery	18	21
Lymph Nodes	20	24
Ki-67		
<2%	26	31
2-20%	33	39
>20%	3	4
Unknown	23	27

Figure 1. QLQ-GI.NET21 Scores

